Financing Quarterly Statistics, Q2 2020

A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, April-June 2020

During Q2 biopharmas brought in an aggregate $32.3bn in financings and device company fundraising totaled $9.5bn; while in vitro diagnostic firms and research tools players brought in $2bn across the period.

Quarterly Stats_1200x675

During the second quarter, biopharma financing reached $32.3bn, more than doubling Q1’s $13.8bn. The bulk of the fundraising was, like last quarter, from follow-on public offerings, which brought in $13.6bn or 42% of the Q2 total (see Exhibit 1). The stand-out of this group, and also the largest financing of the quarter was messenger RNA (mRNA) therapeutics and vaccines firm Moderna Inc.’s $1.3bn public offering [See Deal]. The company will use the proceeds to begin manufacturing its mRNA-1273 vaccine against SARS-CoV-2, the strain of coronavirus that causes COVID-19, ahead of a potential approval and launch.

Moderna is pursuing the rapid development and manufacture of mRNA-1273 in collaboration with the National Institutes of Health’s National Institute...

More from Deal-Making

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.